Literature DB >> 11123842

Statin trials in progress: unanswered questions.

M H Davidson1.   

Abstract

Five years ago, many critics questioned the value of lipid-lowering therapy. Today, the clinical benefits of statins are well documented, but the challenge remains to fully implement these benefits across the wide spectrum of the at-risk population, and continue to advance our understanding regarding the potential for the benefits of statins across an even broader range of select patient populations.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11123842     DOI： 10.1007/s11883-001-0004-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  10 in total

1.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

2.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

Authors:  F M Sacks; L A Moyé; B R Davis; T G Cole; J L Rouleau; D T Nash; M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  1998-04-21       Impact factor: 29.690

3.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

Authors:  A M Gotto; E Whitney; E A Stein; D R Shapiro; M Clearfield; S Weis; J Y Jou; A Langendörfer; P A Beere; D J Watson; J R Downs; J S de Cani
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

4.  Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

Authors:  G L Knatterud; Y Rosenberg; L Campeau; N L Geller; D B Hunninghake; S A Forman; J S Forrester; F L Gobel; J A Herd; A Hickey; B J Hoogwerf; M L Terrin; C White
Journal:  Circulation       Date:  2000-07-11       Impact factor: 29.690

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321
  10 in total
  1 in total

Review 1.  Lipoprotein changes with statins.

Authors:  Evan A Stein; Donald M Black
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.